These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 19164214)

  • 1. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy.
    Hildebrandt MA; Yang H; Hung MC; Izzo JG; Huang M; Lin J; Ajani JA; Wu X
    J Clin Oncol; 2009 Feb; 27(6):857-71. PubMed ID: 19164214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3K/PTEN/AKT/mTOR polymorphisms: association with clinical outcome in patients with head and neck squamous cell carcinoma receiving cetuximab-docetaxel.
    Pfisterer K; Fusi A; Klinghammer K; Knödler M; Nonnenmacher A; Keilholz U
    Head Neck; 2015 Apr; 37(4):471-8. PubMed ID: 24421178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.
    Pu X; Hildebrandt MA; Lu C; Lin J; Stewart DJ; Ye Y; Gu J; Spitz MR; Wu X
    Lung Cancer; 2011 Jan; 71(1):82-8. PubMed ID: 20447721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.
    Wang LE; Ma H; Hale KS; Yin M; Meyer LA; Liu H; Li J; Lu KH; Hennessy BT; Li X; Spitz MR; Wei Q; Mills GB
    J Cancer Res Clin Oncol; 2012 Mar; 138(3):377-85. PubMed ID: 22146979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between single-nucleotide polymorphisms in the PI3K-PTEN-AKT-mTOR pathway and increased risk of brain metastasis in patients with non-small cell lung cancer.
    Li Q; Yang J; Yu Q; Wu H; Liu B; Xiong H; Hu G; Zhao J; Yuan X; Liao Z
    Clin Cancer Res; 2013 Nov; 19(22):6252-60. PubMed ID: 24077347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A GG allele of 3'-side AKT1 SNP is associated with decreased AKT1 activation and better prognosis of gastric cancer.
    Wang X; Lin Y; Lan F; Yu Y; Ouyang X; Wang X; Huang Q; Wang L; Tan J; Zheng F
    J Cancer Res Clin Oncol; 2014 Aug; 140(8):1399-411. PubMed ID: 24737346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1.
    Slattery ML; Herrick JS; Lundgreen A; Fitzpatrick FA; Curtin K; Wolff RK
    Carcinogenesis; 2010 Sep; 31(9):1604-11. PubMed ID: 20622004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
    Xu JL; Wang ZW; Hu LM; Yin ZQ; Huang MD; Hu ZB; Shen HB; Shu YQ
    Asian Pac J Cancer Prev; 2012; 13(5):2157-62. PubMed ID: 22901187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The genetic variants in the PTEN/PI3K/AKT pathway predict susceptibility and CE(A)F chemotherapy response to breast cancer and clinical outcomes.
    Li X; Zhang R; Liu Z; Li S; Xu H
    Oncotarget; 2017 Mar; 8(12):20252-20265. PubMed ID: 28423632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic variations in the PI3K-PTEN-AKT-mTOR pathway are associated with distant metastasis in nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy.
    Guo Q; Lu T; Chen Y; Su Y; Zheng Y; Chen Z; Chen C; Lin S; Pan J; Yuan X
    Sci Rep; 2016 Nov; 6():37576. PubMed ID: 27876891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Expression and Prognostic Impact of the PI3K/AKT/mTOR Signaling Pathway in Advanced Esophageal Squamous Cell Carcinoma.
    Wu N; Du Z; Zhu Y; Song Y; Pang L; Chen Z
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818758772. PubMed ID: 29463194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of genetic variations in the PI3K/PTEN/AKT/mTOR pathway in Korean patients with colorectal cancer.
    Kim JG; Chae YS; Sohn SK; Kang BW; Moon JH; Lee SJ; Jeon SW; Park JS; Park JY; Choi GS
    Oncology; 2010; 79(3-4):278-82. PubMed ID: 21412012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The associations of hub gene polymorphisms in PI3K/AKT/mTOR pathway and Schistosomiasis Japonica infection and hepatic fibrosis.
    Xiao Q; Yu H; Zhu X
    Infect Genet Evol; 2020 Nov; 85():104423. PubMed ID: 32554084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3K/Akt/mTOR signaling & its regulator tumour suppressor genes
    Makker A; Goel MM; Mahdi AA; Bhatia V; Das V; Agarwal A; Pandey A
    Indian J Med Res; 2016 May; 143(Supplement):S112-S119. PubMed ID: 27748285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients.
    Chen M; Gu J; Delclos GL; Killary AM; Fan Z; Hildebrandt MA; Chamberlain RM; Grossman HB; Dinney CP; Wu X
    Carcinogenesis; 2010 Aug; 31(8):1387-91. PubMed ID: 20530239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
    Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
    Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway predict tumor response and disease-free survival in locally advanced rectal cancer patients receiving preoperative chemoradiotherapy and radical surgery.
    Peng J; Ma W; Zhou Z; Gu Y; Lu Z; Zhang R; Pan Z
    J Cancer; 2018; 9(6):1067-1077. PubMed ID: 29581786
    [No Abstract]   [Full Text] [Related]  

  • 20. Diet and colorectal cancer: analysis of a candidate pathway using SNPS, haplotypes, and multi-gene assessment.
    Slattery ML; Lundgreen A; Herrick JS; Caan BJ; Potter JD; Wolff RK
    Nutr Cancer; 2011 Nov; 63(8):1226-34. PubMed ID: 21999454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.